https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/dr-wendy-heywood-awarded-investigator-initiated-research-proposal-shire-pharmaceuticals/
Dr Wendy Heywood awarded investigator initiated research proposal from Shire Pharmaceuticals
28 Jun 2016, 2:01 p.m.
Following NIHR Great Ormond Street BRC support, which led to the creation of a high-throughput targeted proteomic urine test, Dr Wendy Heywood has been awarded an industry investigator initiated award from Shire Pharmaceuticals.
This award is for a Great Ormond Street Hospital (GOSH) research nurse to facilitate the clinical sample collection pipeline and manage a database of patient samples and clinical information. This Rare Disease Sample Collection will allow researchers at the UCL Institute of Child Health (ICH) and clinicians from the GOSH Metabolic disease clinic, to find new biomarkers, new disease mechanisms, design new treatments and test patients.
This streamlined ICH-GOSH collaboration will enable translation of current and future new metabolic disease biomarkers to clinical laboratories for use in future clinical trials of existing and novel therapies.
Could adapting our sinks help combat super bugs?
Discover how a Consultant Microbiologist at GOSH turned an innovative idea into a patented product that could revolutionise infection control in hospitals, schools, and airports – helping to stop superbugs like MRSA.
Millions in new funding for revolutionary paediatric intensive care trial
Researchers at Great Ormond Street Hospital (GOSH) have received more than £6m in funding from the National Institute for Health and Care Research (NIHR).
Twelve days of Research and Innovation at GOSH
It’s been a busy year for Research and Innovation at GOSH, with a number of ground breaking research trials, advanced data projects and technology pilots. To round off the year, here are just twelve of the stories (and amazing staff and researchers) that
Duchenne Muscular Dystrophy gene therapy trial highlights complexity of disease
The first large-scale trial of gene therapy for the debilitating neuromuscular disease, Duchenne Muscular Dystrophy (DMD) has been carried out